Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q1 EPS of $0.11, $0.25 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $11.13 million versus the consensus estimate of $9.88 million.

GUIDANCE:

Aquestive Therapeutics Inc. sees FY2023 revenue of $42-46 million, versus the consensus of $39.061 million.

For earnings history and earnings-related data on Aquestive Therapeutics Inc. (AQST) click here.